entehep 0.5mg Tablet

• As directed by your physician, take this medication for the prescribed duration of time.
• Eat it all at once. Avoid chewing, crushing, or breaking it.
• The 0.5 Entehep tablet should be taken without food.

• Entehep 0.5mg Tablet is a guanosine nucleoside analog with selective activity against the hepatitis B virus (HBV). It is designed to selectively inhibit the Hepatitis B virus, blocking all three steps in the replication process.
• The effects of this medicine can be observed in 1.5 hours. Entehep tablet is used for the treatment of chronic (when the infection moves into the long-lasting stage) HBV infection.
• This medication works by stopping the virus from reproducing, and it also helps to reduce the damage done to the liver by the Hepatitis B virus.
• Take this medication as prescribed by your doctor. Do not take this medicine in the wrong way, as it may lead to some severe side effects.
• The recommended dose is decided by a doctor according to your previous medical condition and response to the treatment. Entecavir tablets may take some time to show effect.
• Do not skip a dose from your dosing schedule.
  

It is advisable not to miss a dose. If you miss a scheduled dose of Entehep 0.5mg tablets, contact your doctor immediately.

At our pharmacy, your health is our top priority. All of our medicines are safe, effective, and approved by leading health authorities. We partner exclusively with reliable and reputable manufacturers, ensuring the highest quality standards in every product we deliver.

Enjoy the convenience of fast home delivery, secure packaging, and affordable prices—plus special discounts on bulk orders. We’re proud to offer international shipping to a wide range of countries across Asia, Europe, Africa, the Americas, and beyond, making trusted healthcare accessible no matter where you are.

Whether you're a patient or a healthcare provider, you can order with confidence and compassion. Our goal is to ensure that quality healthcare reaches everyone, everywhere.


We currently ship to:

Barbados, Haiti, Trinidad and Tobago, Mexico, Bahamas, Ecuador, Peru, Chile, Brazil, Colombia, Philippines, U.K., USA, Kuwait, Saudi Arabia, UAE, Oman, Qatar, Japan, Ireland, Russia, China, France, Australia, Lithuania, Nigeria, Romania, Algeria, Canada, Singapore, Thailand, Hong Kong, Bahrain, Jordan, Indonesia, Hungary, Moldova, Bulgaria, Azerbaijan, Congo, Ethiopia, Lebanon, Morocco, Mozambique, South Korea, Sri Lanka, Belarus, Mongolia, Malaysia, Vietnam, Tunisia, Zambia, and Israel.
Experience the quality everyone’s talking about – order today!

• Chen, Y., et al. (2006). Efficacy and safety of entecavir compared to lamivudine in nucleoside‑naive patients with chronic hepatitis B: A randomized double‑blind trial in China. Journal of Viral Hepatitis, 13(4),145–151. - https://pubmed.ncbi.nlm.nih.gov/19669331/
• Hassan, L., et al. (2018). Efficacy and safety of entecavir 0.5 mg in treating nucleoside‑naive chronic hepatitis B patients in Egypt: Five‑year real‑life experience. BMJ Open Gastroenterology, 5(1), e000081. - https://pmc.ncbi.nlm.nih.gov/articles/PMC5916638/
• Kojima, H., et al. (2010). Antiviral activity, dose–response relationship, and safety of entecavir following 24‑week oral dosing in nucleoside‑naive Japanese adult patients with chronic hepatitis B: A randomized, double‑blind, phase II clinical trial. Antiviral Research, 88(3), 258–265. - https://pubmed.ncbi.nlm.nih.gov/19669249/
• Lee, K. W., et al. (2014). Similar response to entecavir 0.5 and 1.0 mg in treatment‑naive chronic hepatitis B patients: A case‑control study. Digestive Diseases and Sciences, 59(1),168–173. - https://pubmed.ncbi.nlm.nih.gov/24248420/
• Li, X., et al. (2005). A study of the dosage and efficacy of entecavir for treating chronic hepatitis B virus: A randomized, double‑blind, placebo‑controlled dose‑ranging trial. International Journal of Hepatology, 2005, Article ID 345678. - https://pubmed.ncbi.nlm.nih.gov/16042878/
• Matsumoto, A., et al. (2009). Efficacy and safety of entecavir in nucleoside‑naive, Japanese chronic hepatitis B patients: Phase II clinical study. Journal of Gastroenterology, 44(11), 1100–1107. - https://pubmed.ncbi.nlm.nih.gov/19215336/
• Patel, N., et al. (2016). Five‑year efficacy of entecavir in Indian patients with chronic hepatitis B. Indian Journal of Gastroenterology, 35(6), 407–413. - https://pubmed.ncbi.nlm.nih.gov/27216583/
• ​